New oral treatment for rheumatoid arthritis
Official title: Novel first-in-class Therapeutics for Rheumatoid Arthritis
Funded at Biotherapeutics, INC. · NIH-10696749 · Data updated 2026-11-12
This study is working on a new pill to help people with rheumatoid arthritis by targeting a specific part of the immune system to reduce inflammation and improve symptoms.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Biotherapeutics, INC. NIH-funded |
| Lab location | 1 site (Blacksburg, United States) |
| Project start | September 7, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $295,924 |
| NIH project number | 1R43AR082207-01A1 |
| Project ID | NIH-10696749 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with rheumatoid arthritis who are seeking new treatment options.
✕Less likely to help
Patients with rheumatoid arthritis who are currently well-managed on existing therapies may not benefit from this research.
What this research studies
This research focuses on developing a novel oral therapeutic specifically designed for rheumatoid arthritis (RA). The approach combines advanced computational modeling with experimental techniques to create a small-molecule drug that targets a newly identified pathway involved in inflammation and immune response. By testing this drug in animal models, the researchers aim to demonstrate its effectiveness in reducing disease severity and inflammation. The ultimate goal is to provide a safer and more effective treatment option for patients suffering from RA.
Why it matters
Potential benefit: If successful, this research could lead to a new, safer oral treatment option for patients with rheumatoid arthritis.
How similar studies have gone: While this approach is innovative, similar research has shown promise in developing new therapeutics for inflammatory diseases.
Where this research is happening
-
Biotherapeutics, INC.
Blacksburg, United States Active
Researchers
- Principal investigator: Bassaganya-Riera, Josep — Biotherapeutics, INC.
- Study coordinator: Bassaganya-Riera, Josep
Related research
Other NIH-funded projects on the same topics.
-
Gut microbes and methotrexate: boosting RA treatment through microbiome targets
Researchers are studying how gut bacteria affect how well methotrexate works for people with rheumatoid arthritis, aiming to make MTX effective for more patients.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
-
Role of Stabilin receptors in rheumatoid arthritis
A short study to understand how certain scavenger receptors may influence the development and progression of rheumatoid arthritis in adults.
-
IgG glycosylation and endothelial FcγRIIB: understanding RA-related heart and blood vessel disease
This project looks at how rheumatoid arthritis affects blood vessels and clotting, with the goal of uncovering new ways to prevent heart and stroke risk for people with RA.
-
Risk factors and biomarkers for progression of subclinical RA-related lung disease
This study follows people with rheumatoid arthritis to understand who develops lung disease and what biomarkers predict it.
-
Pregnancy changes in rheumatoid arthritis and new treatment ideas
This research seeks to understand why some women’s rheumatoid arthritis improves during pregnancy and how to predict and mimic that effect to make treatments safer and more effective for pregnant patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.